Purpose: Tegafur/gimeracil/oteracil (S-1) and capecitabine plus oxaliplatin (CAPOX) are standard adjuvant chemotherapies (ACs) administered after gastrectomy to patients with stage II or III gastric cancer. However, the efficacy of AC in elderly patients remains unclear.
Adjuvant Chemotherapy in Elderly Patients

INTRODUCTION

Gastric cancer was the fifth most common cancer worldwide and the fourth leading cause of cancer-related death in 2020 [1], and the incidence is gradually increasing as the population ages [2]. A Japanese nationwide registry found that the median age of patients who underwent gastrectomy is 67 years [3]. The proportions of elderly patients who undergo gastrectomy for gastric cancer are approximately 28% (>70 years of age) in Korea [4] and 47% (>75 years of age) in Japan [5]. However, current guidelines for gastric cancer treatment are predominantly based on clinical trials of patients aged 75–80 years [6,7].

Two pivotal prospective randomized studies of adjuvant chemotherapy (AC) after D2 dissection in patients with advanced gastric cancer found beneficial effects for AC using tegafur/gimeracil/oteracil (S-1) or capecitabine plus oxaliplatin (CAPOX). However, subgroup analysis of the elderly population in the ACTS-GC study found that AC with S-1 did not improve relapse-free survival (RFS) or overall survival (OS) compared with surgery alone [8,9]. In the CLASSIC study, patients treated with CAPOX had significantly better RFS and similar OS compared with patients treated with surgery alone [9,10]. Evidence of the efficacy of AC for elderly patients is limited [9,11,12]. Thus, most clinicians have difficulty developing AC treatment plans for elderly patients because they have a higher incidence of comorbidities, greater risk of adverse events, and shorter life expectancies [13]. Most clinicians empirically choose monotherapy (S-1) for elderly patients and combination therapy (CAPOX) for younger patients [14].

This multicenter cohort study compared the survival outcomes of elderly patients who were treated with S-1 or CAPOX AC after curative gastrectomy for gastric cancer.

The objective of this retrospective multicenter cohort study was to compare the efficacies of S-1 and CAPOX AC in patients aged ≥70 years.

Materials and Methods: Nine hundred eighty-three patients who were treated with AC using S-1 (768 patients) or CAPOX (215 patients) were enrolled in this study. Each patient underwent AC after curative gastrectomy for stage II or III gastric cancer at one of 27 hospitals in the Republic of Korea between January 2012 and December 2013. Relapse-free survival (RFS) and overall survival (OS) were analyzed according to AC regimen and age group.

Results: Of the 983 patients, 254 (25.8%) were elderly. This group had a similar RFS (P=0.099) but significantly poorer OS (P=0.003) compared with the non-elderly group. Subgroup analysis of the non-elderly group revealed no AC-associated differences in survival. Subgroup analysis of the elderly group revealed significantly better survival in the S-1 group than in the CAPOX group (RFS, P<0.001; OS, P<0.001). Multivariate analysis revealed that the CAPOX regimen was an independent poor prognostic factor for RFS (hazard ratio [HR], 1.891; 95% confidence interval [CI], 1.072–3.333; P=0.028) and OS (HR, 2.970; 95% CI, 1.550–5.692; P=0.001).

Conclusions: This multicenter observational cohort study found significant differences in RFS and OS between S-1 and CAPOX AC among patients with gastric cancer aged ≥70 years.

Keywords: Adjuvant chemotherapy; Gastric cancer; Elderly; Survival; Recurrence

Funding
This study was funded by the Korean Gastric Cancer Association, Republic of Korea (grant No. KGCT01BCT) and the National Health Insurance Service, Ilsan Hospital (grant No. NHIC2021CR069). We thank the members of the Surgical Oncology Forum (SOF) study group for their collaboration with this study.

Conflict of Interest
No potential conflict of interest relevant to this article was reported.
Author Contributions

Conceptualization: M.J.S., K.H.I. Data curation: M.J.S., C.S. Formal analysis: M.J.S., C.S. Investigation: C.S., M.J.S., J.S.H., Y.M.W., SYG, OSJ, K.JH, PJM, HH, JYS, HSH, JSH, LSE, LYY, SKW, PS, LCM, KCH, JIH, LHH, CSI, LSI, KCY, CH, SMW, PKH, KS, LMS, KHI. Methodology: M.J.S., K.H.I. Project administration: M.J.S., K.H.I. Resources: C.S., M.J.S., J.S.H., Y.M.W., SYG, OSJ, KJH, PJM, HH, JYS, HSH, JSH, LSE, LYY, SKW, PS, LCM, KCH, JIH, LHH, CSI, LSI, KCY, CH, SMW, PKH, KS, LMS, KHI. Software: C.S., K.H.I. Supervision: C.S., M.J.S., J.S.H., Y.M.W., SYG, OSJ, KJH, PJM, HH, JYS, HSH, JSH, LSE, LYY, SKW, PS, LCM, KCH, JIH, LHH, CSI, LSI, KCY, CH, SMW, PKH, KS, LMS, K.H.I. Validation: M.J.S., K.H.I. Visualization: C.S., M.J.S., J.S.H., Y.M.W., SYG, OSJ, KJH, PJM, HH, JYS, HSH, JSH, LSE, LYY, SKW, PS, LCM, KCH, JIH, LHH, CSI, LSI, KCY, CH, SMW, PKH, KS, LMS, K.H.I. Writing - original draft: M.J.S., C.S., K.H.I. Writing - review & editing: C.S., M.J.S., J.S.H., Y.M.W., SYG, OSJ, KJH, PJM, HH, JYS, HSH, JSH, LSE, LYY, SKW, PS, LCM, KCH, JIH, LHH, CSI, LSI, KCY, CH, SMW, PKH, KS, LMS, KHI.

MATERIALS AND METHODS

Patients

Retrospective data were collected from the medical records of 983 patients who underwent radical gastrectomy and D2 lymph node dissection. Each patient underwent surgery at one of 27 hospitals in the Republic of Korea between January 2012 and December 2013. After surgery, all patients were treated with AC for gastric cancer. The inclusion criteria were as follows: age ≥20 years, pathologic stage II or III gastric cancer after curative gastrectomy (R0) according to the American Joint Committee on Cancer staging system [15], and postoperative S-1 or CAPOX AC. The exclusion criteria were as follows: synchronous or metachronous cancer, neoadjuvant chemotherapy, tumor cells present on cytological examination of peritoneal wash fluid, and distant metastasis. We classified patients aged ≥70 years as elderly and patients aged <70 years as non-elderly. Each patient was assigned to 1 of 4 groups based on AC regimen and completion status: S-1 group with completion of AC, S-1 group without completion of AC, CAPOX group with completion of AC, and CAPOX group without completion of AC.

Study design

Medical records and clinical data were reviewed in May 2019. The primary endpoint was 5-year RFS after curative gastrectomy. RFS was defined as the time from the day of surgery to the day of disease relapse. OS was defined as the time from the day of surgery to the day of death from any cause. The Institutional Review Board of Severance Hospital, Yonsei University College of Medicine approved this study (4-2021-0754).

AC regimens

AC was administered according to the ACTS-GC and CLASSIC trial protocols [8,16]. Each patient in the S-1 group was administered the treatment at a dose of 40, 50, or 60 mg (based on body surface area) twice per day for 4 weeks, followed by a 2-week rest period. This 6-week S-1 treatment cycle was repeated for a total of 8 cycles over 12 months. Each patient in the CAPOX group was administered oral capecitabine (1,000 mg/m² twice daily on days 1-14 of each 3-week cycle) and intravenous oxaliplatin (130 mg/m² on day 1 of each 3-week cycle) for a total of 8 cycles over 6 months.

Survival outcomes

During the AC treatment period, each patient underwent abdominal computed tomography (CT) or endoscopy every 3–4 months. After completion of the 8 AC cycles, follow-up medical consultations, including history taking, physical examination, clinical evaluation, and abdominal CT with or without endoscopy, were performed every 3–4 months for the first 2 years and then every 6 months for the next 3 years. Annual or biennial follow-up assessments were performed starting at approximately 5 years post-surgery. If the findings at follow-up suggested cancer recurrence, abdominal ultrasound, chest CT, positron emission tomography, abdominal magnetic resonance imaging, and/or bone scans were performed.

Statistical analysis

IBM SPSS statistics version 25 software (IBM Corp., Armonk, NY, USA) was used for the statistical analysis. The Mann-Whitney U test or Student’s t-test was used to compare independent continuous variables. The χ² test was used to compare independent categorical variables. RFS and OS were estimated using the Kaplan-Meier method, and survival differences between groups were assessed using the log-rank test. Risk factors associated with survival were evaluated using the Cox proportional hazards model.
with OS and RFS in elderly patients were identified using both univariate and multivariate 
Cox proportional hazards models. Statistical significance was set at \( P<0.05 \).

**RESULTS**

**Clinicopathologic characteristics of elderly and non-elderly patients**

Of the 983 patients, 254 (25.8%) were elderly. The results of the between-group comparisons 
(elderly vs. non-elderly) of clinicopathologic characteristics are presented in Table 1. In the 
elderly group, there were significantly higher proportions of patients who were women 
(\( P=0.021 \)), with a low BMI (\( P=0.027 \)), with a high American Society of Anesthesiologists 
(ASA) score (\( P=0.001 \)), with a histologically differentiated type (well-differentiated or 
moderately differentiated adenocarcinoma, \( P=0.014 \)), and with an intestinal-type Lauren 
classification (\( P=0.003 \)). The elderly group had significantly lower rates of CAPOX 
administration (\( P<0.001 \)) and planned chemotherapy completion (\( P<0.001 \)).

**Comparison of the clinicopathologic characteristics of the elderly patients in 
the S-1 and CAPOX groups**

Of the 254 elderly patients, 225 (88.6%) were treated with S-1, and 29 (11.4%) were treated 
with CAPOX. The clinicopathological characteristics of the elderly patients in the 2 AC 
groups are presented in Table 2. When compared with the CAPOX group, the S-1 group was 
associated with smaller tumor size (\( P=0.004 \)), differentiated type tumors (\( P=0.011 \)), and an 
ASA score of 2 (\( P=0.022 \)). The between-group difference in the completion rate of planned 
AC was not significant (52.4% vs. 48.3%, \( P=0.672 \)).

**Survival outcomes**

The median and longest follow-up periods were 59.0 and 87.6 months, respectively. The 
 survival curves of all patients stratified by age are shown in Fig. 1. The difference in RFS 
between elderly and non-elderly patients was not significant (Fig. 1A, \( P=0.099 \)). However, we 
found a significant difference in OS between the 2 groups (Fig. 1B, \( P=0.003 \)).

Survival curves for the non-elderly and elderly groups stratified by AC regimen are presented 
in Fig. 2. In the non-elderly patient group, the differences in RFS (Fig. 2A, \( P=0.281 \)) and OS 
(Fig. 2B, \( P=0.570 \)) were not significant, whereas in the elderly patient group, the differences 
in RFS (Fig. 2C, \( P<0.001 \)) and OS (Fig. 2D, \( P<0.001 \)) were significant.

The results of the analysis by cancer stage indicated that, compared with the CAPOX group, 
elderly patients with stage II cancer treated with S-1 had better RFS and OS (Supplementary 
Fig. 1A and B; \( P=0.001 \) and \( P<0.001 \), respectively). For patients with stage III cancer, 
the differences in RFS and OS between the S-1 and CAPOX groups were not significant 
(Supplementary Fig. 1C and D, \( P=0.104 \) and \( P=0.080 \), respectively).

The survival curves for elderly patients stratified by AC regimen and completion status are 
presented in Supplementary Fig. 2. Patients in the CAPOX group who did not complete AC 
had poor RFS and OS compared to those in the other group. The RFS and OS of patients who 
did not complete S-1 AC were similar to those of patients who completed CAPOX AC (\( P=0.632 \) 
and \( P=0.658 \), respectively).
Table 1. Patient characteristics

| Characteristics                  | Age <70 yr (n=729) | Age ≥70 yr (n=254) | P-value |
|----------------------------------|--------------------|--------------------|---------|
| Sex                              |                    |                    | 0.021   |
| Male                             | 516 (70.8)         | 160 (61.0)         |         |
| Female                           | 213 (29.2)         | 94 (37.0)          |         |
| Age (yr)                         | 55.5±9.2           | 74.5±3.7           | <0.001  |
| BMI (kg/m²)                      | 23.4±3.3           | 22.8±3.3           | 0.027   |
| ASA score                        |                    |                    | <0.001  |
| 1                                | 313 (43.1)         | 40 (15.7)          |         |
| 2                                | 364 (50.1)         | 148 (58.3)         |         |
| 3                                | 50 (6.9)           | 63 (24.8)          |         |
| 4                                | 0 (0)              | 3 (1.2)            |         |
| Extent of gastric resection      |                    |                    | 0.276   |
| Subtotal gastrectomy             | 469 (64.3)         | 173 (68.1)         |         |
| Total gastrectomy                | 260 (35.7)         | 81 (31.9)          |         |
| Operative approach               |                    |                    | 0.737   |
| Open                             | 590 (80.9)         | 208 (81.9)         |         |
| Laparoscopic or robot            | 139 (19.1)         | 46 (18.1)          |         |
| T stage                          |                    |                    | 0.324   |
| pT1                              | 40 (5.5)           | 8 (3.1)            |         |
| pT2                              | 106 (14.5)         | 38 (15.0)          |         |
| pT3                              | 351 (48.2)         | 116 (45.7)         |         |
| pT4                              | 232 (31.6)         | 92 (36.2)          |         |
| N stage                          |                    |                    | 0.101   |
| pN0                              | 161 (22.1)         | 42 (16.5)          |         |
| pN1                              | 150 (20.6)         | 59 (23.2)          |         |
| pN2                              | 178 (24.4)         | 54 (21.3)          |         |
| pN3                              | 240 (32.9)         | 99 (39.0)          |         |
| TNM staging                      |                    |                    | 0.055   |
| I                                | 358 (49.1)         | 107 (42.1)         |         |
| II                               | 371 (50.9)         | 147 (57.9)         |         |
| Retrieved lymph nodes            | 46.6±19.1          | 44.6±18.7          | 0.142   |
| Tumor size (cm)                  | 5.7±3.3            | 6.1±3.3            | 0.074   |
| Differentiation                  |                    |                    | 0.014   |
| Well or moderately               | 230 (31.6)         | 100 (39.4)         |         |
| Poorly or signet ring cell       | 448 (61.5)         | 146 (57.5)         |         |
| Other                            | 51 (7.0)           | 8 (3.1)            |         |
| Lauren classification            |                    |                    | 0.003   |
| Intestinal                      | 242 (33.2)         | 104 (40.9)         |         |
| Diffuse                          | 350 (48.0)         | 92 (36.2)          |         |
| Mixed                            | 73 (10.0)          | 23 (9.1)           |         |
| Unknown                          | 64 (8.8)           | 35 (13.8)          |         |
| Lymphatic invasion               |                    |                    | 0.142   |
| Yes                              | 444 (60.9)         | 172 (67.7)         |         |
| No                               | 245 (33.6)         | 72 (28.3)          |         |
| Unknown                          | 40 (5.5)           | 10 (3.9)           |         |
| Vascular invasion                |                    |                    | 0.151   |
| Yes                              | 219 (30.0)         | 93 (36.6)          |         |
| No                               | 477 (65.4)         | 150 (59.1)         |         |
| Unknown                          | 33 (4.5)           | 11 (4.3)           |         |
| AC regimen                       |                    |                    | <0.001  |
| S-1                              | 543 (74.5)         | 225 (88.6)         |         |
| CAPOX                            | 186 (25.5)         | 29 (11.4)          |         |
| Completion of planned chemotherapy|                    |                    | <0.001  |
| Yes                              | 529 (72.6)         | 132 (52.0)         |         |
| No                               | 200 (27.4)         | 122 (48.0)         |         |

Data are shown as mean±SD or number (%).

BMI = body mass index; ASA = American Society of Anesthesiologists; pT = pathologic depth of invasion; pN = pathologic lymph node involvement; TNM = tumor-node-metastasis; AC = adjuvant chemotherapy; S-1 = tegafur/gimeracil/oteracil; CAPOX = capecitabine plus oxaliplatin.
Univariate and multivariate analysis of prognostic factors for survival

Risk factors related to RFS were identified using a Cox regression model (Table 3). Univariate analysis revealed that total gastrectomy, stage, tumor size, differentiation,
CAPOX administration, and completion of planned chemotherapy were associated with RFS ($P<0.05$). Multivariate analysis revealed that advanced stage, larger tumor size, CAPOX administration, and non-completion were independent risk factors for RFS.

**Fig. 1.** RFS and OS of all patients with stage II and III gastric cancer according to age. (A) RFS. (B) OS. RFS = relapse-free survival; OS = overall survival.

**Fig. 2.** Survival comparisons of elderly and non-elderly patient groups according to chemotherapy regimen. (A) RFS in non-elderly patients. (B) OS in non-elderly patients. (C) RFS in elderly patients. (D) OS in elderly patients. S-1 = tegafur/gimeracil/oteracil; CAPOX = capecitabine plus oxaliplatin; RFS = relapse-free survival; OS = overall survival.
Univariate analysis of OS (Table 3) revealed that age, stage, CAPOX administration, and non-completion of planned chemotherapy were independent risk factors. Multivariate analysis identified older age, advanced cancer stage, and CAPOX administration as independent risk factors for OS.

**DISCUSSION**

This multicenter cohort study had several unique findings. First, although RFS survival was similar in the elderly and non-elderly groups, the elderly group had significantly poorer OS than the non-elderly group. This difference in OS might be due to the age difference between the 2 patient groups. Second, subgroup analysis of the non-elderly group showed that RFS and OS were not different for the 2 AC regimens. Third, subgroup analysis of the elderly group showed significantly better RFS and OS for S-1 AC. This survival benefit remained when the groups were stratified by stage (i.e., stages II and III). Among patients with stage...
II cancer, patients treated with S-1 AC had significantly better RFS and OS. Analysis of patients with stage III cancer revealed that those treated with S-1 AC had better RFS and OS, but the differences were not significant. Fourth, compared with CAPOX AC, S-1 AC was an independent factor for favorable RFS and OS.

The superior survival benefit of S-1 compared with CAPOX was in contrast to previous findings of a survival benefit for CAPOX AC (RFS) among elderly patients when compared with surgery only [10] and no survival benefit for S-1 (RFS or OS) when compared with surgery only [7]. This is the first real-world study to directly compare the efficacy of these AC regimens in elderly patients. The survival discrepancy between the previous and present studies might have been caused by differences in AC compliance among the elderly patients. Patients treated with CAPOX AC in the CLASSIC trial had a completion rate of 67%, and those treated with S-1 had a completion rate of 65.7% in the ACTS-GC trial [8,16]. In this study, the S-1 completion rate was higher than the CAPOX completion rate, although the difference was not statistically significant. AC compliance is a prognostic factor for recurrence [17]. An ACTS-GC trial post-hoc analysis showed that patients who completed AC had better survival than those who did not [18].

Toxicity is the most common reason for failure to complete chemotherapy. In the CLASSIC trial, 99% of patients treated with CAPOX AC experienced adverse events of grade one or more, and 56% of patients experienced adverse events of grade 3 or more [16]. In contrast, in the ACTS-GC trial [8], one common reason for withdrawal of S-1 administration was adverse events, including a relatively low incidence of anorexia grade 3 or higher (6.0%). Since old age is a risk factor for severe chemotherapy toxicity during AC [19], S-1 AC might be more beneficial than CAPOX AC for elderly patients with advanced gastric cancer. Elderly patients are a specific subgroup who requires a careful approach to improve outcomes. In elderly patients, age-related changes in pharmacokinetics and pharmacodynamics and the presence of comorbidities increase the risk of toxicity compared to younger patients [20].

Another reason for the better survival of the S-1 group compared with the CAPOX group could be attributed to differences in genetic characteristics and chemo-responsiveness. The results of a comprehensive molecular characterization using The Cancer Genome Atlas database revealed that the microsatellite instability-high (MSI-H) subtype of gastric cancer was diagnosed in relatively elderly patients (median age, 72 years) [21]. An MSI-H tumor study of the benefits of AC in large cohorts of patients with gastric cancer found that AC with fluoropyrimidine alone, such as S-1 or uracil and tegafur/leucovorin, had a significant survival benefit compared with fluoropyrimidine and platinum, including 5-fluorouracil plus cisplatin or CAPOX [22].

This study had some limitations, which were mostly associated with its retrospective design. First, medical records did not include detailed data on chemotherapy-related adverse events. Second, the number of elderly patients treated with CAPOX was low, which undermined the statistical power to identify some differences, especially for the stage III cancer analysis. Nonetheless, to our knowledge, this study is the first study to evaluate the real-world survival outcomes of AC using S-1 or CAPOX post-curative gastrectomy among elderly patients with stage II or III gastric cancer.

In conclusion, the RFS of the elderly group of patients was similar to that of the non-elderly group. We also found a significant difference between AC with S-1 and CAPOX AC in terms of RFS and OS in elderly patients, indicating that S-1 may be a better AC regimen choice after...
curative gastrectomy in elderly patients with stage II and III gastric cancer.

SUPPLEMENTARY MATERIALS

Supplementary Fig. 1
Survival comparison in elderly patients according to chemotherapy. (A) RFS in elderly patients with stage II. (B) OS in elderly patients with stage II. (C) RFS in elderly patients with stage III. (D) OS in elderly patients with stage III.

Click here to view

Supplementary Fig. 2
Survival comparison in elderly patients according to chemotherapy regimen and completion status of adjuvant chemotherapy. (A) RFS in elderly patients. (B) OS in elderly patients.

Click here to view

REFERENCES

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71:209-249.

PUBMED | CROSSREF

2. Jung KW, Won YJ, Hong S, Kong HJ, Im JS, Seo HG. Prediction of cancer incidence and mortality in Korea, 2021. Cancer Res Treat 2021;53:316-322.

PUBMED | CROSSREF

3. Katai H, Ishikawa T, Akazawa K, Isobe Y, Miyashiro I, Oda I, et al. Five-year survival analysis of surgically resected gastric cancer cases in Japan: a retrospective analysis of more than 100,000 patients from the nationwide registry of the Japanese Gastric Cancer Association (2001-2007). Gastric Cancer 2018;21:144-154.

PUBMED | CROSSREF

4. Information Committee of the Korean Gastric Cancer Association. Korean Gastric Cancer Association-led nationwide survey on surgically treated gastric cancers in 2019. J Gastric Cancer 2021;21:221-235.

PUBMED | CROSSREF

5. Numobe S, Oda I, Ishikawa T, Akazawa K, Katai H, Isobe Y, et al. Surgical outcomes of elderly patients with stage I gastric cancer from the nationwide registry of the Japanese Gastric Cancer Association. Gastric Cancer 2020;23:328-338.

PUBMED | CROSSREF

6. Joharatnam-Hogan N, Shiu KK, Khan K. Challenges in the treatment of gastric cancer in the older patient. Cancer Treat Rev 2020;85:101980.

PUBMED | CROSSREF

7. Sasako M, Sakuramoto S, Katai H, Kinoshita T, Furukawa H, Yamaguchi T, et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol 2011;29:4387-4393.

PUBMED | CROSSREF

8. Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007;357:1810-1820.

PUBMED | CROSSREF

9. Chang SH, Kim SN, Choi HY, Park M, Kim RB, Go SI, et al. Adjuvant chemotherapy for advanced gastric cancer in elderly and non-elderly patients: meta-analysis of randomized controlled trials. Cancer Res Treat 2017;49:263-273.

PUBMED | CROSSREF

10. Noh SH, Park SR, Yang HK, Chung HC, Chung JH, Kim SW, et al. Adjuvant capecitabine plus oxaliplatin...
for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. Lancet Oncol 2014;15:1389-1396.

11. Liang Y, Zhao L, Chen H, Lin T, Chen T, Zhao M, et al. Survival analysis of elderly patients over 65 years old with stage II/III gastric cancer treated with adjuvant chemotherapy after laparoscopic D2 gastrectomy: a retrospective cohort study. BMC Cancer 2021;21:196.

12. Kunisaki C, Sato S, Tsuchiya N, Kubo H, Watanabe J, Sato T, et al. Real-world therapeutic outcomes of S-1 adjuvant chemotherapy for pStage II/III gastric cancer in the elderly. Eur Surg Res 2021;62:40-52.

13. Jin Y, Qiu MZ, Wang DS, Zhang DS, Ren C, Bai L, et al. Adjuvant chemotherapy for elderly patients with gastric cancer after D2 gastrectomy. PLoS One 2013;8:e53149.

14. Lee HY, Hwang IG, Park SE, Kim MJ, Park SH, Kang JH, et al. Factors influencing clinicians’ choice of adjuvant S-1 versus capecitabine plus oxaliplatin after curative gastrectomy in patients with gastric cancer. J Cancer 2016;7:1714-1715.

15. Amin MB, Edge SB, Greene FL, Byrd DR, Brookland RK, Washington MK, et al. AJCC Cancer Staging Manual. 8th ed. New York: Springer, 2017.

16. Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet 2012;379:315-321.

17. Lee CM, Yoo MW, Son YG, Oh SI, Kim JH, Kim HI, et al. Long-term efficacy of S-1 monotherapy or capecitabine plus oxaliplatin as adjuvant chemotherapy for patients with stage II or III gastric cancer after curative gastrectomy: a propensity score-matched multicenter cohort study. J Gastric Cancer 2020;20:152-164.

18. Sakuramoto S, Kikuichi S, Watanabe M. Efficacy of S-1 (oral fluoropyrimidine) for gastric cancer. Med Frontline 2009;64:1075-1080.

19. Jeong JH, Ryu MH, Ryoo BY, Lee SS, Park I, Lee SH, et al. Safety and feasibility of adjuvant chemotherapy with S-1 for Korean patients with curatively resected advanced gastric cancer. Cancer Chemother Pharmacol 2012;70:523-529.

20. Kim HS, Kim JH, Kim JW, Kim BC. Chemotherapy in elderly patients with gastric cancer. J Cancer 2016;7:88-94.

21. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 2014;513:202-209.

22. Kim JW, Cho SY, Chae J, Kim JW, Kim TY, Lee KW, et al. Adjuvant chemotherapy in microsatellite instability-high gastric cancer. Cancer Res Treat 2020;52:1178-1187.